Should I prescribe Paxlovid (nirmatrelvir + ritonavir) to an obese 16‑year‑old adolescent who tested positive for COVID‑19?

Should You Prescribe Paxlovid to This Obese 16-Year-Old with COVID-19?

Yes, you should prescribe Paxlovid to this obese 16-year-old with COVID-19, provided the patient weighs ≥40 kg, treatment can be initiated within 5 days of symptom onset, and you have systematically ruled out significant drug-drug interactions using the Liverpool COVID-19 Drug Interaction Tool. 1, 2, 3

Age and Weight Eligibility

• Paxlovid is FDA-approved for patients ≥12 years of age, making this 16-year-old eligible based on age alone. 3
• The patient must weigh at least 40 kg to receive Paxlovid, as safety and efficacy data below this threshold are unavailable. 1
• Confirm the patient's weight before prescribing; if <40 kg, Paxlovid is contraindicated. 1

Obesity as a High-Risk Factor

• Obesity is an independent risk factor for severe COVID-19 outcomes in adolescents, including increased hospitalization, ICU admission, and prolonged respiratory symptoms compared to lean peers. 4, 2
• Obese adolescents have a 2-fold increased risk of hospitalization and are more likely to develop severe disease defined by respiratory rate ≥30 breaths/minute, hypoxia, or organ failure requiring ICU care. 4
• The presence of obesity can result in more severe disease in younger patients, even when age alone would not typically confer high risk. 4
• Real-world evidence demonstrates that Paxlovid reduces all-cause emergency department visits, hospitalization, and death by 39% in obese patients with COVID-19, with consistent benefit across BMI categories (30.0–34.9 kg/m² and 35.0–39.9 kg/m²). 5

Dosing and Administration

• Standard dosing: nirmatrelvir 300 mg (two 150 mg tablets) plus ritonavir 100 mg (one tablet) taken together orally twice daily for 5 days. 1, 3
• Initiate treatment as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset; delays beyond this window markedly diminish effectiveness. 1, 3
• The medication may be taken with or without food. 3

Renal Function Adjustment

• Check estimated glomerular filtration rate (eGFR) before prescribing. 1
• For moderate renal impairment (eGFR 30–59 mL/min), reduce the dose to nirmatrelvir 150 mg (one tablet) with ritonavir 100 mg twice daily for 5 days. 1, 3
• Paxlovid is not recommended in patients with severe renal impairment (eGFR <30 mL/min). 3
• Reassess renal function during treatment if clinical deterioration occurs, as COVID-19 itself can cause acute kidney injury. 1

Hepatic Impairment

• Paxlovid is not recommended in patients with severe hepatic impairment (Child-Pugh Class C), as safety and pharmacokinetic data are lacking. 1, 3
• Use with caution in patients with pre-existing liver abnormalities and monitor hepatic function during treatment. 1

Mandatory Drug-Drug Interaction Screening

This is the single most critical safety step before prescribing Paxlovid to any patient. 1, 3

• Ritonavir is a potent CYP3A4 inhibitor that causes potentially life-threatening drug interactions during the 5-day treatment course and for several days after completion. 1, 3
• Use the Liverpool COVID-19 Drug Interaction Tool to systematically check all concomitant medications for contraindications, required dose adjustments, temporary discontinuations, or additional monitoring. 1, 3
• Common medications requiring attention include:
  • Statins (simvastatin and lovastatin may require temporary discontinuation) 1
  • Immunosuppressants (tacrolimus, cyclosporine—hold or drastically reduce dose) 1, 6
  • Antiarrhythmics (ranolazine is contraindicated) 1
  • Anticoagulants (direct oral anticoagulants may require dose adjustment or temporary switch to low-molecular-weight heparin) 1, 7

Case Report Warning: Tacrolimus Toxicity

• A 16-year-old male with steroid-resistant nephrotic syndrome developed severe tacrolimus toxicity (elevated creatinine, gastrointestinal distress, tremors) after starting Paxlovid, with tacrolimus levels requiring phenytoin to accelerate clearance. 6
• If your patient is on any CYP3A4-metabolized medication, do not prescribe Paxlovid without a detailed interaction review and management plan. 6

Clinical Benefits in This Population

• Paxlovid reduces hospitalization by 39% (absolute risk reduction 0.9 percentage points) and death by 61% (absolute risk reduction 0.2 percentage points) in real-world cohorts. 8
• These benefits are maintained in both vaccinated and unvaccinated individuals and against circulating Omicron subvariants. 8, 9
• In obese patients specifically, Paxlovid is associated with reduced risk of all-cause emergency department visits, hospitalization, and death, with consistent benefit across age groups (4–64 years and ≥65 years) and vaccination status. 5
• Molnupiravir (an alternative antiviral) probably improves recovery and reduces persistent symptoms from 3 to 6 months, but indirect comparisons suggest Paxlovid provides greater reduction in hospitalization. 10

Monitoring and Adverse Effects

• Common adverse effects include dysgeusia (altered taste) and diarrhea, which occur more frequently than with placebo but rarely lead to discontinuation. 1, 3
• Monitor for hypersensitivity reactions (anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis); if these occur, immediately discontinue Paxlovid and initiate supportive care. 3
• Watch for signs of hepatotoxicity (elevated transaminases, clinical hepatitis, jaundice), particularly in patients with pre-existing liver disease. 3
• Reassess renal function during treatment if clinical deterioration occurs. 1

Special Considerations for Adolescents

• Real-world prescribing data show that Paxlovid is prescribed infrequently to children and adolescents, with only 920 prescriptions among 1,496,621 pediatric patients in one large cohort (mean age 17.2 years). 11
• Among adolescent recipients, 64% had chronic or complex chronic disease and 9% had malignant disease, indicating that prescribers appropriately target high-risk patients. 11
• Obesity qualifies as a high-risk condition for severe COVID-19 in adolescents, justifying Paxlovid use in this 16-year-old. 2, 11

When NOT to Prescribe Paxlovid

• Do not prescribe if the patient weighs <40 kg. 1
• Do not prescribe if symptom onset was >5 days ago. 1, 3
• Do not prescribe if severe renal impairment (eGFR <30 mL/min) or severe hepatic impairment (Child-Pugh Class C) is present. 3
• Do not prescribe if the patient is taking medications with life-threatening interactions (e.g., ranolazine) that cannot be safely managed. 1, 3
• Do not prescribe for patients hospitalized primarily for non-COVID conditions who incidentally test positive; clinical judgment should guide whether treatment is appropriate. 1

Alternative Therapies if Paxlovid Is Contraindicated

• Remdesivir (3-day intravenous course) is the preferred alternative for patients with significant ritonavir drug-interaction risk, pregnancy, or severe renal impairment; it does not share the extensive CYP-mediated interaction profile of ritonavir but requires outpatient infusion capability. 12
• Molnupiravir is an oral alternative with lower efficacy but still reduces all-cause mortality and shortens time to recovery; indirect comparisons suggest Paxlovid provides greater reduction in hospitalization. 12, 10

Post-Treatment Follow-Up

• Screen for post-acute sequelae of SARS-CoV-2 infection (PASC) at 4 weeks and 3 months, evaluating fatigue, dyspnea, chest pain, and exercise intolerance. 2
• Refer to multidisciplinary weight-management services for family-based behavioral interventions targeting diet, activity, sedentary behavior, and sleep. 2
• Educate caregivers on warning signs of clinical deterioration: worsening dyspnea, chest pain, fever persisting >3 days, inability to maintain oral intake, or increasing fatigue; prompt medical contact is advised. 2

Vaccination Counseling

• Administer an mRNA COVID-19 vaccine approximately 3 months after symptom onset to reduce severe outcomes in obese adolescents. 2
• Vaccination of 1 million adolescents (12–17 years) with a second mRNA dose prevents an estimated 560 hospitalizations, 138 ICU admissions, and 6 deaths, while causing 39–47 cases of mild, self-limited myocarditis. 2
• Myocarditis risk after the second dose is highest in young males; monitor for chest pain and obtain ECG, cardiac troponin, and echocardiography when symptoms arise. 2

Common Pitfalls to Avoid

• Do not skip the drug-interaction check—this is the most common cause of serious adverse events with Paxlovid. 1, 3
• Do not calculate tidal volume using actual body weight if the patient requires mechanical ventilation; use predicted body weight to prevent ventilator-induced lung injury. 2
• Do not underestimate disease severity based on a benign initial presentation; obese adolescents may conceal significant pathology. 2
• Do not delay hospitalization when respiratory distress emerges (tachypnea >20 breaths/min, SpO₂ <94% on room air, use of accessory muscles), as rapid deterioration carries high risk. 2